Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Ipamorelin is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) and selective agonist of the ghrelin receptor (GHS-R1a), originally developed by Novo Nordisk in Denmark and first characterised in a landmark 1998 paper in the European Journal of Endocrinology by Raun and colleagues
Liang et al., 2017
Patients begin to lose weight, often seeing steady, sustainable fat reduction. Increased satiety and appetite regulation, helping control food intake. Improved insulin sensitivity, reducing the need for additional diabetes medications
Skimping on sleep undermines IGF-1 LR3's potential effects
US$ 22.12
US$ 29.42
US$ 27.84
US$ 23.38
